Shubhshree Bio.
Shubhshree Bio. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
4 of 4 strong
The short version
FY27 revenue target is approximately INR 350+ crores, up from INR 202 crores in FY26, indicating robust growth. FY26 Revenue: INR 202 crore, EBITDA: INR 16 crore, PAT: INR 11 crore with 5.5% PAT margin.
From Shubhshree Bio.'s Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- FY27 revenue target is approximately INR 350+ crores, up from INR 202 crores in FY26, indicating robust growth.
- Plans to expand manufacturing capacity from 450 to 1,000 metric tons per day in FY27 by setting up five new plants.
- Expectation to increase utilization to 100% after raw material season, up from the current 80%.
- Long-term market outlook driven by a growing 5% to 30% biomass fuel mandate in thermal power plants by FY30.
- Growth supported by expanding sales to both thermal power plants (currently 40% revenue) and private sectors (60% revenue) including textiles, pharmaceuticals, chemicals, steel.
2 more points from Shubhshree Bio.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Shubhshree Bio. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans to expand capacity from 450 metric tons per day to 1,000 metric tons per day by FY2027.
- Capex outlay for FY27 is targeted at INR 15 to 20 crores.
- The capex is mainly for establishing five new plants in states like Bihar, Uttar Pradesh, and Karnataka; the site locations and raw material surveys have already been done.
- Plant setup time is approximately three months once orders are received; operations may start in Karnataka next month.
- Last financial year (FY26) H2 capex was around INR 4 crores; more capex was done in H1 FY26.
- The company is considering funding plans for capex, with internal planning underway but no final decision on equity dilution yet.
2 more points from Shubhshree Bio.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Shubhshree Bio. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is no issue with orders currently; demand exceeds supply.
- Thermal power plants demand about 2 lakh metric tons per day but receive only around 20,000 metric tons per day.
- Private sector demand is roughly double that of thermal plants, also facing fuel shortages.
- The company is waiting for Letters of Intent (LOIs) from states like Bihar, Uttar Pradesh, and Karnataka to start new plant expansions.
2 more points from Shubhshree Bio.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Shubhshree Biofuels Energy Ltd's management said in earlier quarters
Others in Industrial Products this season
- Rappid Valves India Ltd (Q4 FY26)
Capacity is well equipped to handle up to ₹120 crores in turnover without significant capex, focusing on higher-value valves rather than volume increase. Key…
- United Heat Transfer Ltd (Q4 FY26)
Current order book is approximately INR 36-37 crores (Page 11). Key concall takeaways from United Heat Transfer Ltd's Q4 FY26 earnings call — and how it ranks…
- Divine Power Energy Ltd (Q4 FY26)
The provided pages (1-7) of the investor presentation titled "Import of CTC Manufacturing Plant in Vimlesh Industries" do not contain any revenue, sales, or…
- Srivasavi Adhesive Tapes Ltd (Q4 FY26)
Revenue grew 22% in FY26 to ₹110 crore, with recent capacity additions (Units 2, 3, 4 operating; Unit 5 in progress and Unit 6 under setup). Key concall…
Arthneeti Pro · Annual
Shubhshree Bio. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shubhshree Bio. Q4 FY26 results?
FY27 revenue target is approximately INR 350+ crores, up from INR 202 crores in FY26, indicating robust growth. FY26 Revenue: INR 202 crore, EBITDA: INR 16 crore, PAT: INR 11 crore with 5.5% PAT margin.
What is Shubhshree Bio. share price analysis?
Shubhshree Bio. currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 17.0 with a market cap of ₹179 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shubhshree Bio. planning capital expenditure?
The company plans to expand capacity from 450 metric tons per day to 1,000 metric tons per day by FY2027.
Keep Shubhshree Bio. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.